Compare EVLV & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVLV | ALVO |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | Luxembourg |
| Employees | 286 | 1460 |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | N/A | N/A |
| Metric | EVLV | ALVO |
|---|---|---|
| Price | $5.80 | $3.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $9.13 | $8.00 |
| AVG Volume (30 Days) | ★ 2.4M | 945.8K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.67 | $13.28 |
| Revenue Next Year | $19.50 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.61 | $2.94 |
| 52 Week High | $8.90 | $9.94 |
| Indicator | EVLV | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 42.84 |
| Support Level | $5.75 | $3.19 |
| Resistance Level | $5.86 | $3.94 |
| Average True Range (ATR) | 0.29 | 0.18 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 42.00 | 21.71 |
Evolv Technologies Holdings Inc is a security technology company pioneering Artificial Intelligence (AI)-powered screening solutions designed to help create safer environments while maintaining efficient visitor flow and a positive visitor experience. It serves customers across a range of end markets, including education, healthcare, sports, live entertainment, tourist attractions, houses of worship, and industrial workplaces. The company operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.